Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT).

doi:10.1016/S0140-6736(16)00004-0

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT).

Lancet (London, England) - 2 Apr 2016

Barlesi Fabrice, Mazieres Julien, Merlio Jean-Philippe, Debieuvre Didier, Mosser Jean, Lena Hervé, Ouafik L'Houcine, Besse Benjamin, Rouquette Isabelle, Westeel Virginie, Escande Fabienne, Monnet Isabelle, Lemoine Antoinette, Veillon Rémi, Blons Hélène, Audigier-Valette Clarisse, Bringuier Pierre-Paul, Lamy Régine, Beau-Faller Michèle, Pujol Jean-Louis, Sabourin Jean-Christophe, Penault-Llorca Frédérique, Denis Marc G, Lantuejoul Sylvie, Morin Franck, Tran Quân, Missy Pascale, Langlais Alexandra, Milleron Bernard, Cadranel Jacques, Soria Jean-Charles, Zalcman Gérard

Abstract excerpt

BACKGROUND: The molecular profiling of patients with advanced non-small-cell lung cancer (NSCLC) for known oncogenic drivers is recommended during routine care. Nationally, however, the feasibility and effects on outcomes of this policy are unknown. We aimed to assess the characteristics, molecular profiles, and clinical outcomes of patients who were screened during a 1-year period by a nationwide programme...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anaplastic Lymphoma Kinase

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Class I Phosphatidylinositol 3-Kinases

Share to France

Share to Gene Rearrangement

Share to Multivariate Analysis

Share to Phosphatidylinositol 3-Kinases

Share to Receptor, ErbB-2

Share to Receptor Protein-Tyrosine Kinases

Source

Open in PubMed

Identifiers

PMID: 26777916
DOI: 10.1016/S0140-6736(16)00004-0

Genes

ALK
BRAF
EGFR
KRAS
ERBB2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT).PMID 26777916Read ↗

Actionable NSCLC Mutation Identification by Comprehensive Genomic Profiling for Clinical Trial Enrollment: The European Program for the Routine Testing of Patients With Advanced Lung Cancer (EPROPA).Semantic proximity Read ↗

Molecular profiling in Italian patients with advanced non-small-cell lung cancer: An observational prospective study.Semantic proximity Read ↗

Improving the turnaround time of molecular profiling for advanced non-small cell lung cancer: Outcome of a new algorithm integrating multiple approaches.Semantic proximity Read ↗

Molecular profiling of advanced non-small cell lung cancer in the era of immunotherapy approach: a multicenter Italian observational prospective study of biomarker screening in daily clinical practice.Semantic proximity Read ↗

Biomarkers and molecular profiling in non-small cell lung cancer: an expanding role and its managed care implications.Semantic proximity Read ↗

Comprehensive Genomic Profiling Facilitates Implementation of the National Comprehensive Cancer Network Guidelines for Lung Cancer Biomarker Testing and Identifies Patients Who May Benefit From Enrollment in Mechanism-Driven Clinical Trials.Semantic proximity Read ↗

Molecular Epidemiology of the Main Druggable Genetic Alterations in Non-Small Cell Lung Cancer.Semantic proximity Read ↗

Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology.Semantic proximity Read ↗

Real-World Survival Outcomes in Non-Small Cell Lung Cancer: The Impact of Genomic Testing and Targeted Therapies in a Latin American Middle-Income Country.Semantic proximity Read ↗

Dealing with NSCLC EGFR mutation testing and treatment: A comprehensive review with an Italian real-world perspective.Semantic proximity Read ↗

Oncogenic alterations in advanced NSCLC: a molecular super-highwaySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.